Evidence that clearance of hepatitis C virus RNA after α-interferon therapy in dialysis patients is sustained after renal transplantation

Journal of the American Society of Nephrology

Volumn 14, Issue 8, 2003, Pages 2092-2098

  Kamar, Nassim ^a   Toupance, Olivier ^c   Buchler, Matthias ^d   Sandres Saune, Karine ^b   Izopet, Jacques ^b   Durand, Dominique ^a   Rostaing, Lionel ^a  

^a CHU RANGUEIL   (France)

^b CHU PURPAN   (France)

^c HÔPITAL MAISON BLANCHE   (France)

^d CHU BRETONNEAU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIMETABOLITE; AZATHIOPRINE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; VIRUS RNA;

ADULT; AGED; ARTICLE; CAUSE OF DEATH; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DISEASE COURSE; DRUG BLOOD LEVEL; FEMALE; FOLLOW UP; HEMODIALYSIS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPHOCELE; MALE; MONONUCLEAR CELL; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RELAPSE; SEPSIS; SEROLOGY; TREATMENT OUTCOME; VIREMIA;

EID: 0042844701     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ASN.0000079613.81511.3C     Document Type: Article

References (29)

1. Morales JM, Campistol JM: Transplantation in the patient with hepatitis C. J Am Soc Nephrol 11: 1343-1353, 2000
2. Izopet J, Rostaing L, Sandres K, Cisterne JM, Pasquier C, Rumeau JL, Duffaut M, Durand D, Puel J: Longitudinal analysis of hepatitis C virus replication and liver fibrosis progression in renal transplant recipients. J Infect Dis 181: 852-858, 2000
3. Rostaing L, Izopet J, Baron E, Duffaut M, Puel J, Durand D: Treatment of chronic hepatitis C with recombinant interferon alpha in kidney transplant recipients. Transplantation 59: 1426-1431, 1995
4. Kamar N, Sandres-Saune K, Selves J, Ribes D, Cointault O, Durand D, Izopet J, Rostaing L: Long-term ribavirin therapy in hepatitis C virus positive renal transplant patients: Effects upon renal function and liver histology. Am J Kidney Dis, in press
5. Izopet J, Rostaing L, Moussion F, Alric L, Dubois M, That HT, Payen JL, Duffaut M, Durand D, Suc JM, Puel J: High rate of hepatitis C virus clearance in hemodialysis patients after interferon-alpha therapy. J Infect Dis 176: 1614-1617, 1997
6. Pol S, Vallet-Pichard A, Fontaine H, Lebray P: HCV infection and hemodialysis. Semin Nephrol 22: 331-339, 2002
7. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, Wollman J: Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1: 431-435, 1981
8. Poynard T, Bedossa P, Opolon P: Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 349: 825-832, 1997
9. Pasquier C, Daudin M, Righi L, Berges L, Thauvin L, Berrebi A, Massip P, Puel J, Bujan L, Izopet J: Sperm washing and virus nucleic acid detection to reduce HIV and hepatitis C virus transmission in serodiscordant couples wishing to have children. AIDS 14: 2093-2099, 2000
10. Rostaing L, Chatelut E, Payen JL, Izopet J, Thalamas C, Ton-That H, Pascal JP, Durand D, Canal P: Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: Clinical implications. J Am Soc Nephrol 9: 2344-2348, 1998
11. Huraib S, Tanimu D, Romeh SA, Quadri K, Al Ghamdi G, Iqbal A, Abdulla A: Interferon-alpha in chronic hepatitis C infection in dialysis patients. Am J Kidney Dis 34: 55-60, 1999
12. Campistol JM, Esforzado N, Martinez J, Rosello L, Veciana L, Modol J, Casellas J, Pons M, de Las Cuevas X, Piera J, Oliva JA, Costa J, Barrera JM, Bruguera M: Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients: Pre- and post-renal transplantation assessment. Nephrol Dial Transplant 14: 2704-2709, 1999
13. Degos F, Pol S, Chaix ML, Laffitte V, Buffet C, Bernard PH, Degott C, Carnot F, Riffaud PC, Chevret S: The tolerance and efficacy of interferon-alpha in haemodialysis patients with HCV infection: A multicentre, prospective study. Nephrol Dial Transplant 16: 1017-1023, 2001
14. Hanrotel C, Toupance O, Lavaud S, Thiefin G, Brodard V, Ingrand D, Diebold MD, Wynckel A, Chanard J: Virological and histological responses to one year alpha-interferon-2a in hemodialyzed patients with chronic hepatitis C. Nephron 88: 120-126, 2001
15. Pereira BJ, Levey AS: Hepatitis C virus infection in dialysis and renal transplantation. Kidney Int 51: 981-999, 1997
16. Gane E, Pilmore H: Management of chronic viral hepatitis before and after renal transplantation. Transplantation 74: 427-437, 2002
17. Rostaing L, Izopet J, Cisterne JM, Arnaud C, Duffaut M, Rumeau JL, Puel J, Durand D: Impact of hepatitis C virus duration and hepatitis C virus genotypes on renal transplant patients: Correlation with clinicopathological features. Transplantation 65: 930-936, 1998
18. Rostaing L, Izopet J, Sandres K, Cisterne JM, Puel J, Durand D: Changes in hepatitis C virus RNA viremia concentrations in long-term renal transplant patients after introduction of mycophenolate mofetil. Transplantation 69: 991-994, 2000
19. Barrett S, Kieran N, Ryan E, O'Keane JC, Crowe J: Intrahepatic hepatitis C viral RNA status of serum polymerase chain reaction-negative individuals with histological changes on liver biopsy. Hepatology 33: 1496-1502, 2001
20. Barrett S, Ryan E, Crowe J: Serum versus intrahepatic HCV RNA and liver histology in anti-HCV-positive serum PCR-negative individuals. Hepatology 37: 223-224, 2003
21. McHutchison JG, Poynard T, Esteban-Mur R, Davis GL, Goodman ZD, Harvey J, Ling MH, Garaud JJ, Albrecht JK, Patel K, Dienstag JL, Morgan T: Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin. Hepatology 35: 688-693, 2002
22. Rentenaar RJ, van Diepen FN, Meijer RT, Surachno S, Wilmink JM, Schellekens PT, Pals ST, van Lier RA, ten Berge IJ: Immune responsiveness in renal transplant recipients: Mycophenolic acid severely depresses humoral immunity in vivo. Kidney Int 62: 319-328, 2002
23. Legendre C, Garrigue V, Le Bihan C, Mamzer-Bruneel MF, Chaix ML, Landais P, Kreis H, Pol S: Harmful long-term impact of hepatitis C virus infection in kidney transplant recipients. Transplantation 65: 667-670, 1998
24. Huraib S, Iqbal A, Tanimu D, Abdullah A: Sustained virological and histological response with pretransplant interferon therapy in renal transplant patients with chronic viral hepatitis C. Am J Nephrol 21: 435-440, 2001
25. Cruzado JM, Casanovas-Taltavull T, Torras J, Baliellas C, Gil-Vernet S, Grinyo JM: Pretransplant interferon prevents hepatitis C virus-associated glomerulonephyitis in renal allografts by HCV-RNA clearance. Am J Transplant 3: 357-360, 2003
26. Cosio FG, Sedmak DD, Henry ML, Al Haddad C, Falkenhain ME, Elkhammas EA, Davies EA, Bumgardner GL, Ferguson RM: The high prevalence of severe early posttransplant renal allograft pathology in hepatitis C positive recipients. Transplantation 62: 1054-1059, 1996
27. Baid S, Cosimi AB, Farrell ML, Schoenfeld DA, Feng S, Chung RT, Tolkoff-Rubin N, Pascual M: Posttransplant diabetes mellitus in liver transplant recipients: Risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality. Transplantation 72: 1066-1072, 2001
28. Gursoy M, Guvener N, Koksal R, Karavelioglu D, Baysal C, Ozdemir N, Boyacioglu S, Bilgin N, Erdal R: Impact of HCV infection on development of posttransplantation diabetes mellitus in renal allograft recipients. Transplant Proc 32: 561-562, 2000
29. Yildiz A, Tutuncu Y, Yazici H, Akkaya V, Kayacan SM, Sever MS, Carin M, Karsidag K: Association between hepatitis C virus infection and development of posttransplantation diabetes mellitus in renal transplant recipients. Transplantation 74: 1109-1113, 2002